models. The FUS-CisCAR platform offers a controllable strategy that has the potential to overcome relapse caused by tumor heterogeneity and antigen escape, thus enhancing the durability of CAR T cell therapy.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: